- Clinical impact of ki-67 labeling index in non-small cell lung cancerJan Nyrop Jakobsen
Department of Oncology, Finsencentre, Rigshospitalet, 9 Blegdamsvej, 2100 Copenhagen, Denmark
Lung Cancer 79:1-7. 2013..A predictive impact of ki-67 to treatment in NSCLC remains unclear...
- Irinotecan and bevacizumab in recurrent glioblastoma multiformeJan Nyrop Jakobsen
Copenhagen University Hospital, The Finsencenter, Department of Oncology, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
Expert Opin Pharmacother 12:825-33. 2011..Nevertheless, the GBM patients who respond to treatment with BVZ and irinotecan have survived significantly longer than non-responders, indicating that it could be beneficial for a selection of patients to receive this treatment...
- Review on clinical trials of targeted treatments in malignant mesotheliomaJan Nyrop Jakobsen
Department of Oncology, Finsencentre, Copenhagen, Denmark
Cancer Chemother Pharmacol 68:1-15. 2011..This article is a comprehensive review of all clinical trials evaluating the effect of targeted treatments in MM...
- Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancerJan Nyrop Jakobsen
Department of Oncology, Finsencentre, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
Cancer Chemother Pharmacol 69:289-99. 2012..NSCLC is highly heterogeneous and biomarker expression may vary in different areas within the same tumor. This review explores the tumor heterogeneity and chemotherapy-induced changes in EGFR biomarker status in NSCLC...